Nothing Special   »   [go: up one dir, main page]

DE602005014248D1 - 1,4-bis(carboxymethyl)-6-äbis(carboxymethyl)aminoü-6-methyl-perhydro-1,4-diazepin (aazta)-derivate als liganden in kontrastmitteln mit hoher relaxivität zur verwendung bei der magnetresonanztomographie (mrt) - Google Patents

1,4-bis(carboxymethyl)-6-äbis(carboxymethyl)aminoü-6-methyl-perhydro-1,4-diazepin (aazta)-derivate als liganden in kontrastmitteln mit hoher relaxivität zur verwendung bei der magnetresonanztomographie (mrt)

Info

Publication number
DE602005014248D1
DE602005014248D1 DE602005014248T DE602005014248T DE602005014248D1 DE 602005014248 D1 DE602005014248 D1 DE 602005014248D1 DE 602005014248 T DE602005014248 T DE 602005014248T DE 602005014248 T DE602005014248 T DE 602005014248T DE 602005014248 D1 DE602005014248 D1 DE 602005014248D1
Authority
DE
Germany
Prior art keywords
carboxymethyl
contrastives
aminou
aazta
fairy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005014248T
Other languages
English (en)
Inventor
Silvio Aime
Matteo Galli
Luciano Lattuada
Pierfrancesco Morosini
Fulvio Uggeri
Ramalingam Kondareddiar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Imaging SpA
Original Assignee
Bracco Imaging SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging SpA filed Critical Bracco Imaging SpA
Publication of DE602005014248D1 publication Critical patent/DE602005014248D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Hydrogenated Pyridines (AREA)
DE602005014248T 2004-07-02 2005-06-28 1,4-bis(carboxymethyl)-6-äbis(carboxymethyl)aminoü-6-methyl-perhydro-1,4-diazepin (aazta)-derivate als liganden in kontrastmitteln mit hoher relaxivität zur verwendung bei der magnetresonanztomographie (mrt) Active DE602005014248D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58518104P 2004-07-02 2004-07-02
PCT/EP2005/006956 WO2006002873A2 (en) 2004-07-02 2005-06-28 1 , 4 -bis (carboxymethyl) -6- ' bis ( carboxymethyl) amino ! -6 -methyl- perhydro-1 , 4 diazepine (aazta) derivatives as ligands in high relaxivity contrast agents for use in magnetic resonance imaging (mri )

Publications (1)

Publication Number Publication Date
DE602005014248D1 true DE602005014248D1 (de) 2009-06-10

Family

ID=34971296

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602005014248T Active DE602005014248D1 (de) 2004-07-02 2005-06-28 1,4-bis(carboxymethyl)-6-äbis(carboxymethyl)aminoü-6-methyl-perhydro-1,4-diazepin (aazta)-derivate als liganden in kontrastmitteln mit hoher relaxivität zur verwendung bei der magnetresonanztomographie (mrt)
DE602005014234T Active DE602005014234D1 (de) 2004-07-02 2005-06-28 Kontrastmittel mit hoher relaxivität zur verwendung in der magnetresonanzbilddarstellung (mri), enthaltend eine chelatbildende gruppe mit polyhydroxylierten substituenten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602005014234T Active DE602005014234D1 (de) 2004-07-02 2005-06-28 Kontrastmittel mit hoher relaxivität zur verwendung in der magnetresonanzbilddarstellung (mri), enthaltend eine chelatbildende gruppe mit polyhydroxylierten substituenten

Country Status (7)

Country Link
US (2) US7988950B2 (de)
EP (2) EP1765812B1 (de)
JP (2) JP4956426B2 (de)
CN (2) CN1993357B (de)
AT (2) ATE430146T1 (de)
DE (2) DE602005014248D1 (de)
WO (3) WO2006002874A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004038134B4 (de) * 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
WO2007042504A2 (fr) 2005-10-07 2007-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
JP5064761B2 (ja) * 2005-12-21 2012-10-31 富士フイルム株式会社 ジエチレントリアミン型金属キレート構造を有する高級脂肪酸トリエステル及びアミド誘導体
EP1964846A1 (de) * 2007-02-27 2008-09-03 Bracco Imaging, S.P.A. Herstellungsverfahren für Kontrastmittel
US8320647B2 (en) 2007-11-20 2012-11-27 Olea Medical Method and system for processing multiple series of biological images obtained from a patient
EP2147684A1 (de) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Selektiv gegen Metallproteasen wirkende Diagnosemittel
WO2010063080A1 (en) 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
KR101142730B1 (ko) * 2009-03-16 2012-05-04 가천의과학대학교 산학협력단 상자성-이노시톨 포스페이트 복합체를 이용한 자기공명영상용 조영제
KR101253100B1 (ko) * 2010-02-16 2013-04-10 경북대학교 산학협력단 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용
US8765977B2 (en) * 2010-03-31 2014-07-01 General Electric Company Hydroxylated contrast enhancement agents and imaging method
US8722020B2 (en) * 2010-03-31 2014-05-13 General Electric Company Hydroxylated contrast enhancement agents
US8362281B2 (en) 2010-03-31 2013-01-29 General Electric Company Intermediates for hydroxylated contrast enhancement agents
EP2639227A1 (de) * 2012-03-14 2013-09-18 Bracco Imaging S.p.A Neue Klasse von Diazepinderivatchelatbildnern und Komplexe mit paramagnetischen Metallen als MRI-Kontrastmittel
CN104602715A (zh) 2012-09-07 2015-05-06 伯拉考成像股份公司 用于MRI的包含金属两亲配合物的顺磁性固体脂质纳米颗粒(pSLN)
EP3101012A1 (de) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Neue gadoliniumchelat-verbindung zur verwendung in der magnetresonanzbildgebung
EP3183009B1 (de) * 2015-09-30 2023-08-09 Duke University Kontrastmittel zur magnetresonanzabbildung
JP6896733B2 (ja) * 2015-12-10 2021-06-30 ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． 二量体造影剤
WO2017147418A1 (en) 2016-02-24 2017-08-31 Ohio State Innovation Foundation Methods and devices for contrast agent magnetic resonance imaging
GB201610738D0 (en) 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
CA3044877A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
JP7145156B2 (ja) 2016-12-12 2022-09-30 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 二量体造影剤
KR102550339B1 (ko) 2016-12-21 2023-07-04 지이 헬스케어 에이에스 Mri 영상화제로서 적합한 테트라아자비시클로-매크로사이클 기재의 망가니즈 킬레이트 화합물
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
DE102017129405A1 (de) 2017-12-11 2019-06-13 Universitätsklinikum Jena Neue DAZA-Chelatoren als Liganden in der Leberbildgebung
CN111712477B (zh) * 2017-12-20 2024-02-02 通用电气公司 阴离子螯合物化合物
WO2020099398A1 (en) 2018-11-12 2020-05-22 Bracco Imaging Spa Chelating aazta conjugates and complexes thereof
EP3883613A1 (de) 2018-11-23 2021-09-29 Bayer Aktiengesellschaft Formulierung für kontrastmittel und verfahren zur herstellung davon
WO2024018761A1 (ja) * 2022-07-19 2024-01-25 国立大学法人北海道大学 中性脂質及び脂質ナノ粒子

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3129906C3 (de) 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
IE61746B1 (en) 1987-07-16 1994-11-30 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
GB9320277D0 (en) * 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
DE4009119A1 (de) * 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
IT1245853B (it) * 1990-11-16 1994-10-25 Bracco Spa 1,3-bis(3-(mono o poliidrossi)acilamino-5-(mono o poliidrossi-alchil) aminocarbonil-2,4,6-triiodo-benzoil-amino)-idrossi- o idrossi-alchil- propani, loro metodo di preparazione e mezzi di contrasto roentgenografici che li contengono
IT1252180B (it) 1991-12-10 1995-06-05 Bracco Ind Chimica Spa 5,5'-(1,3-propandiil) bis (imino (2-osso-2,1-etandiil)acetilimino)-bis(2,4,6-triiodo-1,3-benzendicarbossiamidi),loro metodo di preparazione e mezzi di contrasto roentgenografici che li contengono
US5324503A (en) 1992-02-06 1994-06-28 Mallinckrodt Medical, Inc. Iodo-phenylated chelates for x-ray contrast
FR2694559B1 (fr) 1992-08-06 1994-10-28 Atta Nouveaux dérivés amphiphiles d'aminoacides ou de peptides, leur procédé de préparation et leur utilisation dans des préparations à usage biomédical.
US5330743A (en) 1992-11-12 1994-07-19 Magnetic Research, Inc. Aminosaccharide contrast agents for magnetic resonance images
DE4318369C1 (de) * 1993-05-28 1995-02-09 Schering Ag Verwendung von makrocyclischen Metallkomplexen als Temperatursonden
DK0661279T3 (da) * 1993-12-30 2001-07-16 Guerbet Sa Polyaminiserede ligander, metalkomplekser, fremgangsmåde til deres fremstilling og diagnostiske og terapeutiske anvendelser
IT1274038B (it) 1994-07-29 1997-07-14 Bracco Spa Chelanti macrociclici loro chelati e relativi usi in campo diagnostico
DE19508058A1 (de) 1995-02-21 1996-08-22 Schering Ag Verfahren zur Herstellung von DTPA-Tetraestern der terminalen Carbonsäuren und deren Verwendung zur Herstellung pharmazeutischer Mittel
DE19646762B4 (de) * 1996-11-04 2004-05-13 Schering Ag Verwendung von Metallverbindungen zur Herstellung von Mitteln zur Strahlentherapie von Tumoren
IT1291624B1 (it) 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
DE19719033C1 (de) * 1997-04-29 1999-01-28 Schering Ag Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
CA2309749A1 (en) * 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
WO1999031045A1 (fr) 1997-12-18 1999-06-24 Kissei Pharmaceutical Co., Ltd. Derives d'acide phenylaminoalkylcarboxylique et compositions medicamenteuses les contenant
DE19849465A1 (de) * 1998-10-21 2000-04-27 Schering Ag Dimere Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
US6342598B1 (en) * 1998-11-26 2002-01-29 Bracco International B.V. Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents
FR2793795B1 (fr) 1999-05-21 2001-08-03 Guerbet Sa Isomeres de tetramides du complexe de gadolinium de l'acide (1,4,7,10-tetrazacyclododecane)1,4,7,10-tetra(2-glutarique) leur procede de preparation et leur application en imagerie medicale
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
DE19959084B4 (de) 1999-12-08 2005-05-12 Schott Ag Organisches LED-Display und Verfahren zu seiner Herstellung
IT1315263B1 (it) 1999-12-21 2003-02-03 Bracco Spa Composti chelanti,loro chelati con ioni metallici paramagnetici, loropreparazione ed uso
AU2001234478A1 (en) 2000-01-21 2001-07-31 Mallinckrodt, Inc. Chelating agents and method for their use as tandem metal chelators and hydrophilic spacers for medical diagnosis and therapy
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
CA2410887C (en) 2000-06-02 2012-07-24 Bracco Research Usa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
DE10064467C2 (de) * 2000-12-15 2002-10-31 Schering Ag Lithium-Komplexe von N-(1-Hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecan, deren Herstellung und Verwendung
ITMI20011518A1 (it) 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
ITMI20011708A1 (it) 2001-08-03 2003-02-03 Bracco Imaging Spa Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
FR2836916B1 (fr) 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese

Also Published As

Publication number Publication date
JP5106107B2 (ja) 2012-12-26
US8540966B2 (en) 2013-09-24
EP1765812B1 (de) 2009-04-29
WO2006002873A2 (en) 2006-01-12
ATE430146T1 (de) 2009-05-15
ATE429933T1 (de) 2009-05-15
DE602005014234D1 (de) 2009-06-10
EP1786475B1 (de) 2009-04-29
US20070258905A1 (en) 2007-11-08
EP1786475A2 (de) 2007-05-23
US7988950B2 (en) 2011-08-02
CN1993357B (zh) 2011-10-19
JP4956426B2 (ja) 2012-06-20
EP1765812A1 (de) 2007-03-28
US20110256067A1 (en) 2011-10-20
CN1993357A (zh) 2007-07-04
WO2006002875A1 (en) 2006-01-12
WO2006002873A3 (en) 2007-05-10
CN101090739B (zh) 2012-10-10
WO2006002874A1 (en) 2006-01-12
JP2008505141A (ja) 2008-02-21
CN101090739A (zh) 2007-12-19
JP2008505142A (ja) 2008-02-21

Similar Documents

Publication Publication Date Title
DE602005014248D1 (de) 1,4-bis(carboxymethyl)-6-äbis(carboxymethyl)aminoü-6-methyl-perhydro-1,4-diazepin (aazta)-derivate als liganden in kontrastmitteln mit hoher relaxivität zur verwendung bei der magnetresonanztomographie (mrt)
HRP20060449T3 (en) Process for the preparation of (1s)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane, acid additon salts thereof and its use for the synthesis of ivabradine and for its pharmaceutically acceptable acid addition salts
AR050278A1 (es) Composiciones de silano, proceso para su preparacion y composiciones de caucho que las contienen
MX2008014898A (es) Composicion para el diagnostico de enfermedades relacionadas con amiloides.
MX2023010737A (es) Nuevo agente de contraste para utilizar en imagenes por resonancia magnetica.
DE60313585D1 (de) Oligomere der gadolinium chelate, ihre verwendung als nmr-kontrastmittel und zwischenverbindungen
TW200721203A (en) Oxide magnetic material and method for producing the same, ferrite sintering magnet and method for producing the same
WO2007121453A3 (en) 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
MXPA04000559A (es) Sistema catalizador que contiene ni (o).
TW200621786A (en) Condensed pyrazole derivatives, their preparation and application in therapeutics
GEP20115211B (en) Terphenyl derivatives for treatment of alzheimer' s disease
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
PT1466947E (pt) Composto azo
MY151102A (en) Photosensitive resin composition, and photosensitive element, resist pattern formation method and printed circuit board production method each utilizing same
CY1107101T1 (el) Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ
Laurent et al. Bifunctional Gd (III) and Tb (III) chelates based on a pyridine–bis (iminodiacetate) platform, suitable optical probes and contrast agents for magnetic resonance imaging
DE60111382D1 (de) Modifizierte polyamide, zusammensetzungen auf basis dieser polyamide und verfahren zu ihrer herstellung
DE60233338D1 (de) Verbesserte substratabbildung durch reversible bindung an einen paramagnetischen komplex
DE602006005349D1 (de) Verfahren zur herstellung von hydrazon-derivaten
ATE332336T1 (de) Azoverbindungen
WO2001051095A3 (de) Paramagnetische dota-derivate, diese enthaltende pharmazeutische mittel, verfahren zu ihrer herstellung und ihre verwendung für das nekrose- und infarkt-mr-imaging
WO2009104457A8 (ja) 複屈折フィルムおよび偏光素子
DE602004025213D1 (de) Neue cyclodextrinderivate, herstellungsverfahren dafür und verwendung davon zur solubilisierung von pharmakologisch wirksamen substanzen
Tei et al. A new bifunctional GdIII complex of enhanced efficacy for MR-molecular imaging applications
Hayashi et al. Water‐proton relaxivity of hyperbranched polymers carrying TEMPO radicals

Legal Events

Date Code Title Description
8364 No opposition during term of opposition